1Anna P. Koo, Therapeutic apheresis in autoimmune and rheumatic diseases[lJ. 1 Clin Apheresis, 2000, 15:18- 27.
2American College of Rheumatology Subcommittee on Rheuma?toid Atthrifts Guidelines. Guidelines for the manage?ment of rheumatoid atthritis( 2002update)[lJ. l.Arthri?tis Rheum, 2002, 46: 328-3416.
4Xiaoxia Yu, et al. A Controlled Study of Double Filtration Plasmapheresis in the Treatment of Active Rheumatoid Arthritis[lJ. 1 Clin Rheumato1 2007,13: 193-198.
5Yukihiro Matsuda,et al. Double Filtration Plasmapheresis for the Treatment of a Rheumatoid Arthritis Patient with Extremely High Level of C-reactive Protein[lJ. Therapeu?tic Apheresis and Dialysis, 2004, 8:404-408.
6Zbigniew M. Szczepiorkowski, et al. Guidelines on the Use of Therapeutic Apheresisin Clinical Practicevidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis[lJ. 1 Clin Apheresis, 2010, 25:83-177.
7Yu X; Wang L, et al. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis[lJ. 1 Rheumatol, 2012, 39:1171-1178.
8Y.Ueki, et al. A multicenter study of leukocytapheresis in rheumatoid arthritis[lJ. Clin Exp Rheumatol, 2007, 25: 810-816.
9Yukinao Sakai, et al. Efficacy of High-Throughput Leukocytapheresis for Rheumatoid ArthritisWith a Reduced Response to Infliximab[lJ. Therapeutic Apheresis and Dialysis, 2009, 13:179-185.
10Teruhisa Azuma et a1. Improved response to inf1 iximab after leukocytapheresis in a patent withrheumatoid ar?thritis[lJ.Mod Rheumatol, 2007, 17:253-255.
